ERBB2 and mucinous neoplasm: Our group recently reported on the most frequently observed molecular alterations across mucinous tumors, observing KRAS mutations in 43.6 % MCs and 78.8 % MBOTs and ERBB2 amplification/overexpression in 18.8 % MCs and 6.2 % MBOTs, the latter being assessed by immunohistochemistry, fluorescent- and chromogenic-in situ hybridization (IHC, FISH & CISH) [13].